Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 21Lymphoid 18Myeloid 8Other solid neoplasm 6Thoracic 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Neoplasm Metastasis 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
navitoclax × Thoracic × Clear all
NCT03366103 2023-10-17

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 14 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT00445198 2018-06-06

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

AbbVie

Phase 1/2 Completed
86 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡